More than 90% of patients receiving the Alzheimer’s drug lecanemab in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers has said.
Lecanemab, developed by Eisai and Biogen and put on sale in December 2023, removes amyloid beta from the brain to slow the progress of Alzheimer’s disease. The research team examined data on the health
WACOCA: People, Life, Style.